Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix 3-Month Dosing Extension Study
NCT00268892Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jan 2006
- Primary completion
- Sep 2009
- Modality
- Peptides, Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label trial of degarelix in prostate cancer (PCa) (3 arms), sponsored by Ferring Pharmaceuticals. Primary endpoints: Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight at 4.5 years and Liver Function Tests at 4.5 years. Started Jan 2006; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00268892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268892.